IL3RA and hematopoietic and lymphoid system neoplasm: The noteworthy ones among them are MB-102 (NCT04109482 and NCT02159495) and UniCAR02-T (NCT04230265), both targeted for relapsed or refractory CD123 hematologic neoplasms and BPDCN patients [65,69,70] (Figure 2).